ACE inhibitors

•	An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients Koro CE, Fu Q, Stender M Pharmacoepidemiol Drug Saf. 2008;17(10):989-986
•	Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: result of the (DREAM) trial. DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S. Diabetes Care. 2008 May;31(5):1007-14. Epub 2008 Feb 11.
•	Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Kunz R, Friedrich C, Wolbers M, Mann JF Arch Intern Med. 148(1):30-48
•	Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, for the BENEDICT Study Group J Am Soc Nephrol. 2006;17:3472-3481
•	Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Barzilay JI, Davis BR, Cutler JA, et al, for the ALLHAT Collaborative Research Group Arch Intern Med. 2006;166:2191-2201
•	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INVEST study) Cooper-Dehoff R, Cohen JD, Bakris GL, et al, for the INVEST Investigators Am J Cardiol.. 2006;98:890-894
•	Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus Andersen NH, Poulsen SH, Poulsen PL, et al Clin Sci (Lond). 2006;111:53-59
•	Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J Am J Kidney Dis.. 2005;46:1080-1087
•	For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy? Penmetsa S, Simmons M, Daugird A J Fam Pract. 2005;54:711-713
•	Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP) Niklason A, Hedner T, Niskanen L, Lanke J J Hypertens. 2004;22:645-652
•	The Importance of Blood Pressure Control in the Patient With Diabetes Bakris GL Am J Med. 2004;116(Suppl 5A):30S-38S
•	Effect of Nurse-Directed Diabetes Care in a Minority Population Davidson MB Diabetes Care. 2003;26:2281-2287
•	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Chobanian AV, Bakris GL, Black HR, et al. JAMA. 2003;289:2560-2571
•	Measures for Reducing the Incidence of Events in Patients With CVD Are Available but Too Often Are Not Applied
•	Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/Beta-Blocker-Based Treatment Regimen Niskanen L, Hedner T, Hansson L, et al. Diabetes Care. 2001;24:2091-2096
•	Ramipril and the Development of Diabetes
•	Controlling Blood Pressure in Hypertensive Diabetic Patients Reduces the Risk of Cardiovascular Events and Mortality, Regardless of the First-line Antihypertensive Agent Employed
•	130/80 mm Hg: The New and Lower BP Goal for Adults With Hypertension and Diabetes
•	In Hypertensive Diabetic Patients, ACE Inhibitors Lower Blood Pressure, Reduce the Risk of CVD Events, and Lower the Overall Mortality Rate
•	Elderly Diabetic Patients Hospitalized for AMI in Michigan Have Not Always Received the Most Effective Treatment Mehta RH, Ruane TJ, McCargar PA, Eagle KA, Stalhandske EJ. Arch Intern Med. 2000;160:1301-1306
•	Management Strategies for Hypertension and Diabetes Am J Med. 2000;108:238-245
•	Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.

Disclaimer Statement - Privacy Statement